Binimetinib, an MEK inhibitor, is protected by patent WO2003077914A1, which outlines synthesis steps and key reagents. The patent details the preparation of binimetinib through a multi-step process involving specific chemical reactions and intermediates.
What are the key synthesis steps for binimetinib?
The synthesis described in WO2003077914A1 involves several stages, typically starting with readily available building blocks. One common pathway involves the preparation of a pyrimidine intermediate, followed by coupling reactions to introduce the requisite side chains. The process often includes steps like amide formation, cyclization, and further functionalization to arrive at the final binimetinib molecule.
What reagents are critical for binimetinib synthesis?
Specific reagents are crucial for achieving high yields and purity in binimetinib synthesis. These can include activating agents for amide bond formation, bases for promoting condensation reactions, and catalysts for cross-coupling. Solvents play a vital role in controlling reaction kinetics and solubility. For example, coupling reagents such as carbodiimides or activating esters might be used, alongside bases like DIPEA or triethylamine.
When does the patent for binimetinib expire?
Patent WO2003077914A1 has an application date of March 5, 2003, and a publication date of September 25, 2003. The expiry date of a patent depends on various factors, including national validations and potential extensions. Information regarding the specific expiry dates in different regions can be found on patent databases like DrugPatentWatch.com.
Who manufactures and sells binimetinib?
Binimetinib is marketed by Array BioPharma, which was acquired by Pfizer. It is available under the brand name Mektovi®, often in combination with encorafenib for the treatment of certain types of melanoma.
What is the mechanism of action for binimetinib?
Binimetinib is a highly selective inhibitor of MEK1 and MEK2 enzymes [1]. These enzymes are part of the MAPK/ERK signaling pathway, which is frequently hyperactivated in various cancers, including melanoma. By inhibiting MEK, binimetinib blocks downstream signaling, thereby suppressing cell proliferation and promoting apoptosis in cancer cells dependent on this pathway.
How does binimetinib work with encorafenib?
Binimetinib is commonly used in combination with encorafenib, a BRAF inhibitor. This combination targets the BRAF/MEK pathway by inhibiting two key nodes. Encorafenib blocks BRAF, which is often mutated in melanoma, while binimetinib inhibits MEK, downstream of BRAF. This dual blockade is designed to be more effective than inhibiting either target alone and can overcome resistance mechanisms [1].
What are the indications for binimetinib?
Binimetinib, typically in combination with encorafenib, is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [1].
What are the side effects associated with binimetinib?
Common side effects of binimetinib can include gastrointestinal issues like nausea, vomiting, diarrhea, and abdominal pain. Other reported side effects may involve fatigue, rash, fever, and elevated liver enzymes. Serious adverse events can include cardiac dysfunction, ocular toxicity, and development of secondary malignancies.
Are there biosimilars or generics of binimetinib?
As of now, there are no approved biosimilars or generic versions of binimetinib available. The patent landscape, as detailed in WO2003077914A1, would be a primary factor influencing the timeline for generic market entry.
How is binimetinib's patent protection structured?
Patent WO2003077914A1 covers the composition of matter and methods of synthesis for binimetinib. Additional patents may exist covering specific formulations, polymorphs, or methods of use, which can further extend market exclusivity.
Sources:
1. https://drugpatentwatch.com/medicines/binimetinib